What Fueled The Previous Growth In The Anakinra Market?
The anakinra market has seen considerable growth due to a variety of factors.
• There has been a speedy expansion of the anakinra market in the past few years, and it is projected to surge from $4.89 billion in 2024 to $5.51 billion in 2025, with a compound annual growth rate (CAGR) of 12.8%.
The significant growth during the historic period can be traced back to factors like the escalating incidences of rheumatoid arthritis, the endorsement of anakinra for managing uncommon autoinflammatory conditions such as NOMID, the rising consciousness regarding biologics for controlling chronic inflammatory ailments, and heightened utilization of targeted therapies.
How Does the Forecast Look for the Anakinra Market Size In The Coming Years?
The anakinra market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of anakinra is predicted to experience a quick expansion in the coming years, with an expectation to reach $8.81 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 12.4%.
The projected boom during this period is due to the widening range of conditions for which anakinra is indicated, an escalating concentration on customized healthcare, rising number of rare autoinflammatory disorders, advancements in medicine delivery systems, as well as the ever-improving healthcare accessibility in burgeoning markets, thus amplifying the demand for biologics. Main trends in the forecast period encompass the creation of biosimilars and the novel generation of IL-1 inhibitors, the proliferation of home-based and self-administered treatment methodologies, alliances between biotechnological firms and academic bodies, and the progression of digital health strategies to ensure patient compliance.
What Are The Leading Drivers Of Growth In The Anakinra Market?
The escalating prevalence of autoimmune disorders is anticipated to boost the expansion of the anakinra market. These disorders, characterized by the body mistakenly attacking its own healthy tissues and organs as if they were foreign threats, are increasingly common due to genetic susceptibility and environmental factors, like infections, pollution, and changes in diet. Anakinra, which counteracts interleukin-1 (IL-1) activity, is used to manage the inflammation triggered by autoimmune disorders including rheumatoid arthritis, Still’s disease and periodic fever syndromes. This is evidenced by a report released in June 2024 by the Australian Institute of Health and Welfare, a government agency in Australia, which found that during 2021-22 there were 10,000 hospitalizations due to rheumatoid arthritis. This marked a 25% rise from the previous year's 8,000, equaling a rate of 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune disorders is stimulating the anakinra market’s development.
How Are The Segments Defined Within The Global Anakinra Market?
The anakinra market covered in this report is segmented –
1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease
2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease
3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms
4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares
5) By Adult-Onset Still's Disease: Active Disease, Remission Induction
6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management
7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis
Pre-Book The Anakinra Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Anakinra Market?
Leading corporations in the Anakinra market are obtaining regulatory consent to broaden their scope for novel therapeutic uses. Official permissions from regulatory authorities for a drug's marketing and distribution for certain medical conditions after assessing its efficacy, safety, and quality are what regulatory approvals comprise of. For example, in November 2022, the US-based government organization, the Food and Drug Administration, issued Emergency Use Authorization (EUA) for Kineret (anakinra) intended for treating adults hospitalized due to COVID-19-induced pneumonia who required additional oxygen, with the end goal of mitigating severe respiratory failure risk. The approval was derived from the SAVE-MORE Phase 3 trial outcomes demonstrating that beginning treatment with Kineret enhanced patient prognosis. Kineret operates by hindering cytokines IL-1a and IL-1ß, instrumental in triggering the hyperinflammatory reaction in extreme COVID-19 situations. While it hasn't received complete FDA approval for this purpose, it has been given authorization for short-term use during the public health crisis.
Who Are the Key Players In The Anakinra Market?
Major companies operating in the anakinra market are:
• Swedish Orphan Biovitrum AB
• Boehringer Ingelheim
• Amgen Inc.
What Is The Most Dominant Region In The Anakinra Market?
North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
